With the activation of IL-1ß signaling and dysregulation of CD20 B immune cells being prominent examples illustrating the common involvement of inflammation and a dysregulated immune balance in cancer and CVD, this minireview addresses how further inspired by the CANTOS trial, anti-IL-1ß drugs are beyond CVD and heart failure, evaluated in cancer, and how vice versa the anti-CD20 monoclonal antibody (rituximab), the first therapeutic antibody approved for oncology patients, is evaluated in the context of CVD and heart failure. This evidence concerns the gene IL1B and cancer.